Insider Selling: InspireMD (NYSE:NSPR) Insider Sells $28,500.66 in Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 17,593 shares of the stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $1.62, for a total value of $28,500.66. Following the completion of the transaction, the insider directly owned 1,174,664 shares in the company, valued at approximately $1,902,955.68. This represents a 1.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shane Thomas Gleason also recently made the following trade(s):

• On Monday, February 2nd, Shane Thomas Gleason sold 2,000 shares of InspireMD stock. The shares were sold at an average price of $1.60, for a total value of $3,200.00.
• On Friday, January 30th, Shane Thomas Gleason sold 2,900 shares of InspireMD stock. The shares were sold at an average price of $1.63, for a total transaction of $4,727.00.
• On Thursday, January 29th, Shane Thomas Gleason sold 5,000 shares of InspireMD stock. The stock was sold at an average price of $1.65, for a total transaction of $8,250.00.
• On Wednesday, January 28th, Shane Thomas Gleason sold 12,395 shares of InspireMD stock. The stock was sold at an average price of $1.65, for a total transaction of $20,451.75.
• On Tuesday, January 27th, Shane Thomas Gleason sold 4,781 shares of InspireMD stock. The shares were sold at an average price of $1.66, for a total transaction of $7,936.46.
• On Thursday, January 22nd, Shane Thomas Gleason sold 8,411 shares of InspireMD stock. The stock was sold at an average price of $1.57, for a total transaction of $13,205.27.
• On Tuesday, January 20th, Shane Thomas Gleason sold 2,955 shares of InspireMD stock. The shares were sold at an average price of $1.59, for a total transaction of $4,698.45.
• On Friday, January 16th, Shane Thomas Gleason sold 2,250 shares of InspireMD stock. The shares were sold at an average price of $1.61, for a total value of $3,622.50.
• On Thursday, January 15th, Shane Thomas Gleason sold 2,909 shares of InspireMD stock. The shares were sold at an average price of $1.58, for a total value of $4,596.22.

InspireMD Price Performance

Shares of NSPR stock opened at $1.64 on Thursday. The business has a 50-day moving average of $1.81 and a 200 day moving average of $2.15. InspireMD, Inc. has a 1-year low of $1.51 and a 1-year high of $3.80. The stock has a market capitalization of $69.45 million, a PE ratio of -2.19 and a beta of 0.93.

Analyst Ratings Changes

Separately, Maxim Group began coverage on shares of InspireMD in a research report on Monday. They set a “buy” rating and a $6.00 price target for the company. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $5.00.

Institutional Investors Weigh In On InspireMD

Several institutional investors and hedge funds have recently modified their holdings of the stock. Aberdeen Group plc boosted its stake in shares of InspireMD by 27.9% during the 4th quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock valued at $5,649,000 after purchasing an additional 692,247 shares in the last quarter. Velan Capital Investment Management LP lifted its holdings in InspireMD by 137.1% in the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock worth $5,166,000 after buying an additional 1,239,669 shares during the period. Parkman Healthcare Partners LLC boosted its position in InspireMD by 97.6% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after acquiring an additional 1,205,328 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in shares of InspireMD by 45.7% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock worth $8,137,000 after acquiring an additional 1,058,467 shares during the period. Finally, Millennium Management LLC raised its position in shares of InspireMD by 766.3% in the 3rd quarter. Millennium Management LLC now owns 147,423 shares of the company’s stock worth $355,000 after acquiring an additional 130,405 shares in the last quarter. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.